|
|
 |
|
20 MARCH 2011
|
| |
|
This expert interview with Bertrand Tombal, MD, PhD, from Cliniques universitaires Saint-Luc in Brussels, Belgium, and Stephane Oudard, MD, PhD, from Georges Pompidou Hospital in Paris, France, along with an eNewsflash and downloadable slides, discusses newly released data concerning the role of cabazitaxel in the continuum of care for castration-resistant prostate cancer focusing on the following data releases:
From the 26th Annual European Association of Urology Congress:
Abstract #1090: Clinical benefit of cabazitaxel plus prednisone in the TROPIC trial in men with metastatic castration resistant prostate cancer (mCRPC) who progressed after docetaxel-based treatment.
From the 2011 Genitourinary Cancers Symposium:
Abstract #128: Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC).
Abstract #A38: G-CSF prophylaxis reduces the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer.
|
| |
|
|
| |
|
 View the Expert Interview and access the downloadable slides
View eNewsflash |
 |
|
|
|
|
|
